Sentences with phrase «haemophilia a»

Indeed, psychological interventions have been proven to be effective in a broad range of disorders and illnesses.15 — 18 Although a few former works have focused on psychological interventions in haemophilia, showing positive and promising results, 19 — 25 the lack of recent papers exploring this issue is somewhat surprising, despite the recommendations and guidelines that emphasise their relevance.

This is an innovative investigation, applying two empirically sound interventions (cognitive - behavioural therapy and hypnosis) to people with haemophilia.

A36Hemofilia - Qol71: this is an haemophilia - specific self - report questionnaire assessing health - related QoL.

Another noteworthy issue is that psychological or psychiatric conditions are reported by 47 % of PWH, with 29 % relating these symptoms to haemophilia.4 This is even more relevant considering that psychological factors can influence both pain experience and QoL in PWH.12 Interestingly, Cassis et al 6 state that variations in QoL are better explained by psychosocial, rather than clinical predictors.

The current study protocol points to an innovative research that can contribute to better understand the impact and potential benefits of psychological interventions in haemophilia care setting.

Psychosocial health and effective pain management are considered essential end points for optimal haemophilia care, but there is a significant gap in evidence - based treatments targeting these outcomes in people with haemophilia (PWH).

For questions regarding breed survey, hip and elbow dysplasia, tattooing, tooth certificates or haemophilia see the Breed Matters Section: Breed Survey, Hip & Elbow Dysplasia, Tattoo, Tooth Certificates, Haemophilia

Check with your breeder whether their dogs have been screened for haemophilia and hip dysplasia and ask your vet to regularly check your dog's hips.

They can also suffer from a disease called Von Willebrand's Disease, which is similar to haemophilia in humans.

Similar to haemophilia in humans, von Willebrand's disease can result in life - threatening bleeding.

Most of us have heard of haemophilia.

Dogs, and other animals can suffer from haemophilia too.

The Kennel Club also recommends testing for haemophilia and hip dysplasia, other common problems with the breed.

The results from the first human trials for a gene therapy to treat haemophilia A have just been published.

iPS cells have been employed to generate cells for the treatment of various diseases including diabetes, cardiovascular disease, sickle cell anaemia, Parkinson's disease and haemophilia [19]--[23].

The treatment of haemophilia, dialysis and the medical applications of ultrasound are just a few historical examples.

Spark Therapeutics» gene therapy for patients with haemophilia has seen some early success in clinical trials, according to a report published yesterday.

Spark Therapeutics» gene therapy for patients with haemophilia has seen some early success in clinical trials, after being tested in 10 male patients

The results, published in the New England Journal of Medicine, demonstrate the therapy being used to treat 10 male haemophilia patients without significant side effects.

Some concerns had been raised that by infusing patients with such a high activity gene, the treatment would overcorrect for haemophilia and give rise to thrombosis.

The therapy hoped to resolve some of the problems surrounding haemophilia treatment by exchanging the continual infusions for a single vector infusion that could permanently boost Factor IX expression.

«People who live with haemophilia today face a lifelong need for vigilant monitoring and recurrent factor concentrate infusions to prevent spontaneous, potentially life - threatening bleeds and to protect their joints,» said Katherine High, President and Head of Research and Development at Spark Therapeutics.

Almost exactly a year ago, we reported on a gene therapy for haemophilia that was in development by the Children's Hospital of Philadelphia (and subsequently the CHOP spinout Spark Therapeutics).

Ohmori, Tsukasa, et al. «CRISPR / Cas9 - mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.»

Cellectis, the French genome engineering specialist, and VIB together conduct research into new approaches to cure haemophilia.

Professor Pasi continued: «Incredibly exciting is the potential for a significant change in how haemophilia is treated globally.

A hereditary genetic condition dominantly affecting men, people with severe haemophilia A have virtually none of the protein factor VIII which is essential for blood to clot.

There are around 2000 people with severe haemophilia A in the UK.

The «transformational» results have particular significance as the first successful gene therapy trial for the haemophilia A.

A «cure» for haemophilia is one step closer, following results published in the New England Journal of Medcine of a groundbreaking gene therapy trial led by the NHS in London.

We really now have the potential to transform care for people with haemophilia using a single treatment for people who at the moment must inject themselves as often as every other day.

Those short half - lives mean that most people with haemophilia must transfuse themselves every two or three days.

Only about 4 % of people with haemophilia B develop inhibitors to factor IX.

Replacing the clotting ability lacking in haemophilia has been the treatment since the 1840s, when attempts were made to treat people with the disease by transfusion with whole blood from people with normal clotting.

Eloctate, for haemophilia A, was approved in June and is recommended for an initial infusion once every four days, with a physician adjusting that up to five days or down to three as appropriate.

For all the advantages of these extended - life molecules, the researchers predict that they will be supplanted in perhaps a decade by advances in gene therapy, which will enable people with haemophilia to produce their own clotting factors.

Factor IX — which people with haemophilia B lack — lasts longer, 18 — 24 hours.

One 2001 study suggested that up to 40 % of people with severe haemophilia do not follow the prophylactic schedule.

One barrier to haemophilia therapy is the tendency of factor VIII to prompt the body into producing anti-factor VIII antibodies, known as inhibitors.

For the parents of a child born with haemophilia, the diagnosis comes with both good and bad news.

Repairing the faulty genes that cause haemophilia could ultimately cure the disease, but it will be a tough challenge

Disorders like haemophilia that are caused by faults on the X chromosome are therefore more common in males.

Unfortunately, haemophilia A, which is caused by factor VIII deficiency, is about four times as common as haemophilia B.

«We think we can change the whole concept of haemophilia treatment,» Shima says.

The hunt is on for ways to diagnose and treat the joint problems that are now the main chronic problem in haemophilia

As these therapies emerge, dealing with haemophilia will become less troublesome (see below).

Depending on the person, the amount of factor VIII — the protein missing in haemophilia A — in the bloodstream drops by half in a mere 8 — 12 hours.

About 30 % of people with haemophilia A develop inhibitors, and once they do, treating their bleeding becomes much more difficult.

In Madrid last week, Amit Nathwani of the Royal Free NHS Trust in London announced that six people treated for haemophilia using AAV in early 2011 are still producing the blood clotting factor they previously lacked.

2011 Six people with clotting disorder haemophilia B see a reduction in symptoms after gene therapy on liver cells.